Clinical Trials · NCT00917267
A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 691
- Start date
- Jul 2009
- Locations
- 42 sites, 5 countries
- Primary endpoint
- Change in HbA1c From Baseline to Week 26.